What's new in Interventional Cardiology

Aaysha Cader interviews Divaka Perera on the CHIP-BCIS3 randomised trial, which evaluated whether elective left ventricular (LV) unloading during high-risk PCI improves outcomes in patients with severe LV dysfunction, extensive coronary disease, and complex procedures, as presented at ACC.26 in New Orleans.

Nicola Ryan provides her take on the 10-year follow-up of the HOST-EXAM, which was presented by Hyo-Soo Kim at ACC.26 in New Orleans.

A 79-year-old patient previously treated with surgical aortic valve replacement was referred after an episode of acute cardiac decompensation. Although clinically stabilised, further evaluation revealed degeneration of the bioprosthesis, and mixed aortic valve pathology.

This case focuses on the diagnostic assessment and the strategic considerations guiding the...

Nicola Ryan provides her take on DKCRUSH-VIII, a randomised controlled trial comparing IVUS versus angiography guidance for PCI, predominantly using the DKCRUSH technique in patients with complex bifurcation lesions, as presented by Shaoliang Chen at ACC.26 in New Orleans.

Daniele Giacoppo reports and provides his perspective on the main results of the IVUS-CHIP trial, presented by Roberto Diletti from the Erasmus University Medical Center, Rotterdam, the Netherlands, during a Late-Breaking Trials session at the ACC.26 in New Orleans, and simultaneously published in the New England Journal of...

Alex Sticchi interviews Adam B. Greenbaum on the PROTECT head-to-head trial, comparing the new full-body Emboliner device with the first-generation Sentinel during TAVR, as presented at ACC.26 in New Orleans.

Jonathan Curio provides his take on the PRO-TAVI trial presented by Michiel Voskuil at ACC.26 in New Orleans and simultaneously published in The Lancet.

Yohei Ohno provides his takeaways from the results of the SURVIV trial, which were presented by Dimytri Siqueira during the ACC.26 in New Orleans.

Chiara De Biase provides her take on the FAST III Trial presented by Joost Daemen at ACC.26 in New Orleans. She reviews the comparison between vFFR and FFR, highlighting key findings and their impact on revascularisation strategies.

Kalaivani Mahadevan provides an in-depth analysis of the ORBITA-CTO trial: a first-ever randomised, double-blind, placebo-controlled trial evaluating CTO PCI in stable angina patients.
She also interviewed principal investigators Sarosh Khan and John Davies following the LBCT Scientific Session at ACC.26 in New Orleans and simultaneous publication in...